Home/ Stocks/ MBRX

Moleculin Biotech, Inc.

MBRX XNAS

$0.42 -0.60 (-59.08%) ▼ 15-min delayed

Open

$0.88

High

$1.07

Low

$0.31

Volume

17.86M

Market Cap

$7.21M

About Moleculin Biotech, Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 17 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-12,845,000	$-3.54
FY 2025	$0	$-33,560,000	$-28.42
Q3 2025	$0	$-25,399,000	$-0.68
Q2 2025	$0	$-17,809,000	$-1.15

TickerDaily Coverage

Why Is Moleculin Biotech (MBRX) Stock Down 53.9% Today?

Penny Stocks Marcus Rivera · 4h ago

Moleculin Biotech stock plummeted 53.9% Friday, closing at $0.47 after opening at $1.02. The...

View All Coverage →

Get MBRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Moleculin Biotech, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.